GLB-001
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 48 patients (estimated)
- Sponsors
- GluBio Therapeutics Inc.
- Tags
- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor), High Risk
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 1815
- NCT Identifier
- NCT06146257
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.